Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde J L, Labeur C, Seguret-Mace S, Duverger N, Hutchinson G, Vandekerckhove J, Tavernier J, Rosseneu M
Department of Biochemistry, University of Gent, Belgium.
Protein Sci. 1998 Mar;7(3):587-99. doi: 10.1002/pro.5560070307.
The enzyme cholesterol lecithin acyl transferase (LCAT) shares the Ser/Asp-Glu/His triad with lipases, esterases and proteases, but the low level of sequence homology between LCAT and these enzymes did not allow for the LCAT fold to be identified yet. We, therefore, relied upon structural homology calculations using threading methods based on alignment of the sequence against a library of solved three-dimensional protein structures, for prediction of the LCAT fold. We propose that LCAT, like lipases, belongs to the alpha/beta hydrolase fold family, and that the central domain of LCAT consists of seven conserved parallel beta-strands connected by four alpha-helices and separated by loops. We used the conserved features of this protein fold for the prediction of functional domains in LCAT, and carried out site-directed mutagenesis for the localization of the active site residues. The wild-type enzyme and mutants were expressed in Cos-1 cells. LCAT mass was measured by ELISA, and enzymatic activity was measured on recombinant HDL, on LDL and on a monomeric substrate. We identified D345 and H377 as the catalytic residues of LCAT, together with F103 and L182 as the oxyanion hole residues. In analogy with lipases, we further propose that a potential "lid" domain at residues 50-74 of LCAT might be involved in the enzyme-substrate interaction. Molecular modeling of human LCAT was carried out using human pancreatic and Candida antarctica lipases as templates. The three-dimensional model proposed here is compatible with the position of natural mutants for either LCAT deficiency or Fish-eye disease. It enables moreover prediction of the LCAT domains involved in the interaction with the phospholipid and cholesterol substrates.
胆固醇卵磷脂酰基转移酶(LCAT)与脂肪酶、酯酶和蛋白酶共享丝氨酸/天冬氨酸-谷氨酸/组氨酸三联体,但LCAT与这些酶之间的序列同源性较低,因此尚未确定LCAT的折叠结构。因此,我们依靠基于序列与已解析的三维蛋白质结构库比对的穿线法进行结构同源性计算,以预测LCAT的折叠结构。我们提出,LCAT与脂肪酶一样,属于α/β水解酶折叠家族,且LCAT的中央结构域由七个保守的平行β链组成,这些β链由四个α螺旋连接,并由环隔开。我们利用这种蛋白质折叠的保守特征预测LCAT中的功能结构域,并进行定点诱变以定位活性位点残基。野生型酶和突变体在Cos-1细胞中表达。通过酶联免疫吸附测定法(ELISA)测量LCAT质量,并在重组高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和单体底物上测量酶活性。我们确定D345和H377为LCAT的催化残基,F103和L182为氧阴离子孔残基。与脂肪酶类似,我们进一步提出,LCAT中50-74位残基处的潜在“盖子”结构域可能参与酶-底物相互作用。以人胰腺脂肪酶和南极假丝酵母脂肪酶为模板,对人LCAT进行了分子建模。这里提出的三维模型与LCAT缺乏症或鱼眼病的天然突变体的位置相符。此外,它还能够预测参与与磷脂和胆固醇底物相互作用的LCAT结构域。